A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA NSCLC

Grants and Contracts Details

StatusActive
Effective start/end date11/27/19 → 11/7/25

Funding

  • Merck Sharp & Dohme Corporation: $289,256.00